Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828071 | 0.94 | TAAR1 (0.44) | TAAR1HTR2CDDB1CRBNHTR2A | |
| SCHEMBL3162963 | 0.78 | NOS3 (0.37) | ALDH1A1 | |
| SCHEMBL3168135 | 0.78 | HTR2C (0.33) | TAAR1HTR2C | |
| SCHEMBL1849372 | 0.77 | TAAR1 (0.45) | TAAR1HTR2CHTR2AHTR2BALDH1A1 | |
| SCHEMBL8006764 | 0.77 | KMT2A (0.44) | HTR2CHTR2AHTR2BALDH1A1 | |
| SCHEMBL3163224 | 0.77 | KDM1A (0.46) | HTR2CHTR2BMAOAMAOBKDM1A | |
| SCHEMBL3165666 | 0.77 | HTR2C (0.47) | HTR2CHTR2AHTR2BTSHR | |
| SCHEMBL2201865 | 0.77 | HTR6 (0.33) | ALDH1A1TSHR | |
| SCHEMBL4718842 | 0.74 | KDM1A (0.49) | ALDH1A1KDM1A | |
| SCHEMBL290575 | 0.74 | TAAR1 (0.42) | TAAR1HTR2CDDB1CRBNHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479790-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180305360-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2018-10-25 | — | — | US | disclosed |
| US-10035799-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2018-07-31 | — | — | US | disclosed |
| EP-3250209-A1 | COMT INHIBITING METHODS AND COMPOSITIONS | Lieber Institute For Brain Development (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20160222011-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2016-08-04 | — | — | US | disclosed |
| WO-2016123576-A1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035799-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | TAAR1 1180/4885HTR2C 147/4885DDB1 2930/4885 |
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | BDKRB1, BDKRB2, VIPR1 | TAAR1 103/4885HTR2C 1015/4885DDB1 1229/4885 |
| US-20160222011-A1 | COMT Inhibiting Methods and Compositions | COMT, SLC6A3, MAOA | TAAR1 1180/4885HTR2C 147/4885DDB1 2930/4885 |
| US-20180305360-A1 | COMT Inhibiting Methods and Compositions | COMT, SLC6A3, MAOA | TAAR1 1180/4885HTR2C 147/4885DDB1 2930/4885 |
| US-10479790-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | TAAR1 1180/4885HTR2C 147/4885DDB1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.